Comparative Pharmacology
Head-to-head clinical analysis: DHC PLUS versus DI METREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DHC PLUS versus DI METREX.
DHC PLUS vs DI-METREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DHC PLUS is a combination of codeine (an opioid agonist) and homatropine (an anticholinergic). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. Homatropine antagonizes muscarinic acetylcholine receptors, reducing GI motility and secretions, which may decrease opioid-induced nausea and vomiting.
Combination of diphenhydramine (H1-antagonist) and pseudoephedrine (alpha-1 agonist). Diphenhydramine blocks histamine at H1 receptors, reducing allergic symptoms; pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptors, relieving nasal congestion.
1-2 tablets (dihydrocodeine 40 mg/paracetamol 500 mg per tablet) orally every 4-6 hours as needed, maximum 8 tablets per day.
4 mg orally once daily, increased to a maximum of 8 mg once daily if needed.
None Documented
None Documented
3.5-5 hours for dihydrocodeine; prolonged in hepatic impairment (up to 8-10 hours) and may require dose adjustment.
The terminal elimination half-life is approximately 12 hours, requiring twice-daily dosing for steady-state concentrations.
Renal: ~90% as glucuronide conjugates, with 10% as unchanged dihydrocodeine and 5-10% as nordihydrocodeine; biliary/fecal: <5%.
Renal excretion accounts for approximately 70% of elimination as unchanged drug and metabolites; biliary/fecal excretion accounts for the remaining 30%.
Category C
Category C
Antihistamine-Decongestant
Antihistamine-Decongestant